Truist Financial Raises Dianthus Therapeutics (NASDAQ:DNTH) Price Target to $63.00

Dianthus Therapeutics (NASDAQ:DNTH) had its target price raised by equities research analysts at Truist Financial from $56.00 to $63.00 in a report issued on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Truist Financial’s target price indicates a potential upside of 63.88% from the company’s previous close.

Several other equities analysts have also issued reports on DNTH. HC Wainwright upped their target price on Dianthus Therapeutics from $40.00 to $47.00 and gave the company a “buy” rating in a report on Monday, November 10th. Stifel Nicolaus boosted their price objective on Dianthus Therapeutics from $52.00 to $65.00 and gave the stock a “buy” rating in a research report on Friday, September 12th. Wedbush restated an “outperform” rating and issued a $46.00 price objective on shares of Dianthus Therapeutics in a research note on Monday, December 22nd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dianthus Therapeutics in a research report on Wednesday, October 8th. Eight analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $64.43.

Dianthus Therapeutics Price Performance

Shares of DNTH stock traded up $0.35 on Thursday, hitting $38.44. The stock had a trading volume of 160,674 shares, compared to its average volume of 569,610. The business has a 50 day moving average of $40.54 and a 200 day moving average of $31.80. Dianthus Therapeutics has a 12-month low of $13.36 and a 12-month high of $45.46. The stock has a market cap of $1.65 billion, a price-to-earnings ratio of -11.08 and a beta of 1.55.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.97) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($0.11). The firm had revenue of $0.40 million for the quarter, compared to analysts’ expectations of $0.58 million. Dianthus Therapeutics had a negative return on equity of 33.02% and a negative net margin of 4,106.04%. As a group, research analysts expect that Dianthus Therapeutics will post -2.61 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Ryan Savitz sold 20,000 shares of the business’s stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $45.18, for a total value of $903,600.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Simrat Randhawa sold 109,031 shares of the firm’s stock in a transaction that occurred on Friday, November 14th. The stock was sold at an average price of $38.14, for a total transaction of $4,158,442.34. Following the completion of the transaction, the executive vice president directly owned 4,000 shares of the company’s stock, valued at approximately $152,560. This trade represents a 96.46% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 216,538 shares of company stock valued at $8,283,175 in the last quarter. Corporate insiders own 8.15% of the company’s stock.

Institutional Trading of Dianthus Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Raymond James Financial Inc. bought a new position in Dianthus Therapeutics in the second quarter valued at $27,000. Parkside Financial Bank & Trust increased its position in shares of Dianthus Therapeutics by 131.7% during the 3rd quarter. Parkside Financial Bank & Trust now owns 950 shares of the company’s stock valued at $37,000 after purchasing an additional 540 shares during the last quarter. Russell Investments Group Ltd. purchased a new position in shares of Dianthus Therapeutics during the 3rd quarter valued at about $64,000. Tower Research Capital LLC TRC raised its holdings in shares of Dianthus Therapeutics by 330.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock valued at $80,000 after buying an additional 3,317 shares in the last quarter. Finally, AlphaQuest LLC bought a new stake in Dianthus Therapeutics in the 2nd quarter worth approximately $94,000. 47.53% of the stock is currently owned by institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.